Abstract
5-Hydroxytryptamine type 2A receptors (5-HT2A) are G protein-coupled receptors that increase intracellular Ca2+concentrations via activation of phospholipase C-β and elevation of myo-inositol-1,4,5-triphosphate levels. In the central nervous system, these receptors are involved in regulating sleep and alertness. We now report that ethanol inhibited (IC50 = 41 mM) 5-HT2A receptor-induced Ca2+-dependent Cl− currents in Xenopus laevis oocytes. Pharmacologically relevant concentrations of other n-alcohols (propanol to octanol) also inhibited 5-HT responses; however, longer-chain alcohols (decanol, undecanol and dodecanol) had little or no effect. The protein kinase C inhibitor GF109203X and the nonspecific protein kinase inhibitor staurosporine abolished the inhibitory effects of ethanol and octanol on 5-HT2A receptors. GF109203X enhanced 5-HT2Areceptor function when administered alone. In addition, the volatile anesthetics halothane and 1-chloro-1,2,2-trifluorocyclobutane decreased 5-HT2A responses in a concentration-dependent manner. The inhibitory effects of the volatile anesthetics were also attenuated in oocytes treated with GF109203X. The intravenous anesthetics propofol, ketamine, pentobarbital and etomidate did not affect 5-HT2Areceptor function. The modulation of 5-HT2Areceptor-dependent current was also investigated using two novel halogenated compounds that do not produce anesthesia. The nonanesthetic compound 2,3-chloro-octafluorobutane had no effects on 5-HT-induced currents; however, the nonanesthetic compound 1,2-dichlorohexafluorocyclobutane had an inhibitory effect at lower concentrations than the predicted anesthetic concentration. Thus, 5-HT2A receptors are inhibited by alcohols and volatile anesthetics, and these actions are dependent on protein kinase C.
Footnotes
-
Send reprint requests to: Dr. R. Adron Harris, Department of Pharmacology, University of Colorado Health Sciences Center and Veterans Affairs Medical Center, 4200 E. 9th Ave., Box C236, Denver, Colorado, 80262. E-mail: adron.harris{at}uchsc.edu
-
↵1 Supported by the Department of Veterans Affairs, NIH Grants GM 47818 and AA 06399, the Yokoyama Clinical Pharmacology Foundation and the Uehara Memorial Foundation.
-
↵2 K. Minami, M. Minami and R. A. Harris, unpublished observations.
- Abbreviations:
- AMPA
- α-amino 3-hydroxy-5-methyl-4-isoxozolepropionic acid
- DAG
- diacylglycerol
- DMSO
- dimethylsulfoxide
- F3
- 1-chloro-1,2,2-trifluorocyclobutane
- F6
- 1,2-dichlorohexafluorocyclobutane
- F8
- 2,3-chloro-octafluorobutane
- GABA
- γ-aminobutyric acid
- GF
- GF109203X
- GTPγS
- guanosine-5′-O-(3-thio)triphosphate
- HEPES
- 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid
- 5-HT
- 5-hydroxytryptamine
- IP3
- myo-inositol-1,4,5-triphosphate
- MAC
- minimum alveolar concentration
- MBS
- modified Barth’s solution
- NMDA
- N-methyl-d-aspartate
- PLC
- phospholipase C
- Received November 20, 1996.
- Accepted February 14, 1997.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|